Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Primary Care
How would you approach a patient with osteoporosis who remains at risk for osteoporotic fracture and who had an atypical femur fracture on denosumab?
Related Questions
What is your approach to management of patients with recurrent nephrolithiasis and osteoporosis who are receiving teriparatide?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
How long after parathyroidectomy (for parathyroid adenoma with hyperparathyroidism) do you wait before initiating romosuzumab in an older patient with osteoporosis and very high fracture risk?
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
How do you manage osteoporosis treatment following parathyroidectomy for primary hyperparathyroidism?
Is there any concern with starting romosozumab in a patient who is taking raloxifene for a history of breast cancer?
Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?
